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Abstract- The glial cell-line derived neurotrophic factor 
(GDNF) and neurturin (NTN) belong to a structurally 
related family of neurotrophic factors. NTN exerts its effect 
through a multi-component receptor system consisting of 
the GDNF family receptor alpha 2 (GFRα2), proto-
oncogene RET and/or NCAM.  GFRα2 is spliced into at 
least three isoforms, GFRα2a, GFRα2b and GFRα2c. The 
present study investigated the expression and functional 
differences of GFRα2 isoforms. These receptor isoforms are 
differentially expressed in specific human brain regions. 
Using Neuro2A model, GDNF and NTN promote neurite 
outgrowth via GFRα2a and GFRα2c, but not GFRα2b. 
These GFRα2 isoforms regulate different early response 
genes when stimulated with GDNF and NTN. Interestingly, 
using co-expression models, GFRα2b inhibits ligand 
induced neurites outgrowth of GFRα2a and GFRα2c, and 
also the related receptor, GFRα1a. More intriguingly, 
ligands activated GFRα2b was also able to attenuate neurite 
extension induced by an unrelated stimulation using 
retinoic acid. MAPK activation induced by GDNF was not 
attenuated by GFRα2b in a co-expression model, while the 
early response genes expression profile (up-regulation of 
FosB) was similar to that induced by GFRα2b alone. This 
study suggest that GFRα2b is not merely a dominant 
negative isoform, but signals through a yet to be determined 
mechanism to antagonize and inhibit neuritogenesis.  
Together, these data suggest a new paradigm for the 
regulation of growth factor signaling and neurite outgrowth 
via an inhibitory splice variant of the receptor. 
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Neurturin (NTN) and glial cell line-derived 
neurotrophic factor (GDNF) belongs to the GDNF family 
of neurotrophic factors which are secreted, dimeric 
proteins with a cysteine knot structure and may be useful 
as therapeutics for various neurodegenerative diseases 
including Parkinsons Disease [1]. NTN signals through 
its preferred receptor GFRα2 and coupling with Ret and 
NCAM [2-5]. Although they are structurally related, 
NTN differs from GDNF in their distribution, and 
receptor localization [6, 7]. In vivo, the chronic 
administration of NTN produced specific neurochemical 
changes only in ventrolateral striatum with no detectable 
adverse effects, while administration of GDNF resulted 
in weight loss and allodynia, suggesting functional 
differences between these two factors [8].  
Numerous studies have shown that alternative 
splicing is prevalent in metazoan genomes, as a means of 
producing functionally diverse polypeptides from a 
single gene. A recent genome-wide microarray analysis 
has estimated that greater than 74% of human multi-exon 
genes are alternatively spliced [9]. We and others have 
previously identified 2 other mammalian splice variants 
of GFRα2a, GFRα2b and GFRα2c [10, 11]. In addition to 
the existence of spliced isoforms of GFRα2, multiple 
isoforms of GFRα1[12-14] and GFRα4 [15-17] have also 
been reported. The alternatively spliced variants of the 
co-receptors, RET and NCAM have been shown to have 
distinct biochemical and physiological functions. These 
observations are consistent with the emerging view that 
the combinatorial interactions of the spliced isoforms of 
GFRα, RET [18-20] and NCAM[21, 22], may contribute 
to the multi-component signaling system to produce the 
myriad of observed biological responses.  
In this study, the hypothesis that these isoforms have 
differential signaling mechanisms and functional 
consequences was tested. In brief, GFRα2 isoforms 
mediate neurite outgrowth differently and regulate 
distinct expression profiles of early response genes. A 
significant observation is that GFRα2b, was able to 
antagonize the ligand induced neurite extension due to 
GFRα2a and GFRα2c, and also inhibits neurite extension 
induced by retinoic acid. 
 
 
II. MATERIALS AND METHODS 
 
A. Generation of Neuro2A cells expressing GFRα2 
isoforms 
The murine neuroblastoma cell line Neuro2A which 
express endogenous RET and NCAM, was grown in 10% 
fetal bovine serum (FBS, Hyclone USA), at 37°C in 5% 
CO2. Neuro2A cells were stably transfected with either 
GFRα2a, GFRα2b, GFRα2c or pIRESneo (Clontech) 
vector control using Fugene-6 (Roche Lifescience) and 
selected with 0.8 mg/ml of G418, over a period of 2 
 months. Primers used for measuring GFRα2 isoforms 
expression were as previously described [23].  All 
subsequence studies were repeated with 3 individual 
clones.  
 
Fig.1 Ligand- induced differentiation of Neuro2a stably expressing  
GFRα2 isoforms. Cells treated with retinoic acid (RA), GDNF or NTN 
(50 ng/ ml) for 3 days. Percentage of cells bearing neurites which were 
twice the length of the cells body was scored. Similar results were 
repeated with 3 separate clones. Statistical significance was calculated  
between ligand stimulated and control conditions using paired Students 
t-test. A value of P<0.05 was considered significant (*P<0.002).  
  
B. Assessment of differentiation in GFRα2 cells 
induced by GDNF or NTN 
Twenty thousand cells per well were seeded on 6 
wells plate over night, at 10% serum DMEM. Cells were 
then incubated with 0.5% serum media, with or without 
GDNF or NTN (50 ng/ ml). Cells were then incubated 
for further 3 days. Retinoic Acid (5µM) was used as a 
positive control for inducing differentiation. Percentages 
of differentiation were counted for cells bearing neurites 
twice the length of the cells body. More than 600 cells 
from three random areas were counted per well. 
Significant differences in percentage of differences 
between ligand stimulated and control were calculated 
using paired Students t-test. A value of P<0.05 was 
considered significant.  
 
C. Analysis of MAP Kinase (Erk1/2) 
phosphorylation 
 Phosphorylation of Erk1/Erk2 (Erk1/2) was 
analyzed as follows. Cells were seeded in DMEM with 
10% FBS for 24 h, followed by serum depletion (0.5% 
FBS) for 16 h. The cells were then treated with 50 ng/ml 
of GDNF, NTN, Artemin or Persephin (PreproTech, 
England) in serum free media for different time course at 
37 °C. For dose response studies, cells were stimulated 
with different concentration of ligands for 10 min in 37 
°C. Control treatment with 1 M Sorbitol (Sigma) was 
carried out simultaneously. The supernatants were 
removed and cells were washed once with phosphate-
buffered saline (PBS) and subsequently lysed in 2% SDS. 
Protein concentrations were determined using BCA 
(Pierce, Rockland USA). Western blot using phospho-
specific antibodies according to the manufacturer’s 
instructions (Cell Signaling Technologies). Blots were 
stripped and reprobed with actin (Dako) antibodies to 
verify equal loading of protein.  
 
D. Measurements of early response genes regulated 
by GDNF and NTN 
Cells were seeded in DMEM with 10% FBS for 24 h, 
followed by serum depletion (0.5% FBS) for 16 h. The 
cells were then treated with 50 ng/ml of GDNF and NTN 
(PreproTech, England) in serum free media for different 
time course at 37 °C. To terminate, total RNA isolation 
and reverse transcription were performed as described 
above. Quantitative real time PCR were performed as 
mentioned above, using specifically designed primers, in 
parallel with plasmid as standard. The fold changes in the 
target gene, normalized to GAPDH and relative to the 
expression in control sample.  
 
III. RESULTS 
A. GFRα2 isoforms induced different 
morphological changes 
Neuro2A is a mouse neuroblastoma that does not 
express GFRα1 or GFRα2, but express Ret and NCAM, 
the co-receptors of GFRαs (data not shown). Hence, we 
have stably transfected Neuro2A with GFRα2a, GFRα2b, 
or GFRα2c to generate a cell model to study the 
functions of GFRα2 isoforms. GDNF and NTN (50 ng/ 
ml) were able to induce neurites outgrowth in Neuro2A 
cells via GFRα2a and GFRα2c, but not in GFRα2b 
(Fig.1). Retinoic acid served as a positive control for 
neurite outgrowth in all the three GFRα2 isoforms 
transfected cells. The percentage of cells bearing neurites 
in ligand-induced GFRα2a and GFRα2c were 
comparable to those induced by retinoic acid.  
 
 
Fig.2 Ligand induced activation of ERK1/2 in Neuro2a cells stably 
expressing GFRα2 isoforms. Cells were treated with ligand with 
designated time points, phosphorylation of ERK1/2 were detected by 
Western blot analysis. Equal loading were controlled by reprobe for 
actin.  
 B. GDNF and NTN showed some selectivity in 
MAPK activation on GFRα2 isoforms 
NTN phosphorylated ERK1/2 equally well in all 
three GFRα2 isoform transfected cells (Fig.2). However, 
GDNF was only able to induce ERK1/2 activation in 
GFRα2a and GFRα2c, but not GFRα2b. At 
supramaximal dose of GDNF (200 ng/ml), ERK1/2 was 
activated only in GFRα2a and GFRα2c transfected cells 
(data not shown). Interestingly, radioactive labeled 
GDNF binding studies showed that all GFRα2 isoforms 




C. GFRα2 isoforms regulates distinct early response 
genes 
To further understand the mechanisms underlying 
the activation of GFRα2 isoforms, we investigated the 
regulation of some early response genes or transcription 
factors in ligand activated GFRα2 isoforms. The changes 
in expression of genes from fos family (c-fos, fos-B), jun 
family (c-jun, jun-b), egr family (egr1-4), Zinc finger 
protein 393 (Zfp393), and GDNF inducible transcription 
factors mGIF and mGZF1 in GDNF and NTN treated 
GFRα2 isoforms were studied. As summarized in Table 1, 
GFRα2 isoforms regulated different sets of early 
response genes. The expressions of these genes were up-
regulated and peaked (5 to 10 fold increment) at 1 hour 
post ligand treatment, and gradually declined for the next 




Fig. 3 Studies of neuritogenesis inhibition of GFRα2b. (A.) 
Using co-expression model, GFRα2b antagonizes ligand 
induced neurites outgrowth of GFRα2a and GFRα2c. (B.) 
Ligand activated GFRα2b were able to attenuates neurites 
outgrowth induced by retinoic acid (RA) (5 µM).  
 
D. GFRα2b antagonizes neurites outgrowth of  
retinoic acid and ligand activated GFRα2a and GFRα2c 
 To understand the potential combinatorial functions 
of GFRα2 isoforms, we examined the effects of GFRα2b 
on neurite extension due to the other GFRα2 isoforms in 
a co-expression model. GFRα2b was cloned into the 
downstream EMCV IRES driven multiple cloning, while 
GFRα2a or GFRα2c were cloned into the upstream 
multiple cloning driven by a CMV promoter. Intriguingly, 
GFRα2b inhibited the neurite extensions induced by 
GFRα2a and GFRα2c (Fig.3a). Retinoic acid induced 
differentiation in all the cell lines, verifying that 
transfection did not affect the abilities of these cells to 
differentiate. Next, the possibility that GFRα2b may 
attenuate neurites outgrowth induced by non-GFRα  
stimuli was investigated. Using the co-expression cell 
model, GDNF and NTN activated GFRα2b and resulted 
in the inhibition of neurite outgrowth induced by retinoic 
acids (Fig. 3b). 
 We further investigated the effects of GFRα2b on 
signaling and the regulation of early response gene 
expressions induced by GFRα2a/ 2c. Ligand induced 
MAPK (ERK1/2) activations were not affected in the co-
expression model (Fig. 4). However, profiles of ligand 
induced early response genes regulation were that 
induced by GFRα2b activation (fosB was up-regulated) 









Fig. 4 Study of ERK1/2 activation in GFRα2 isoforms co-expression 
model. Neuro2A cells stably co-expressing GFRα2 isoforms were 
treated with ligand for 10 min. ERK1/2 phosphorylation was analyzed 
by Western blot. Equal loading of protein were confirmed with reprobe 




Alternative RNA splicing is a commonly used 
strategy for creating a functionally diverse pool of gene 
products derived from a single gene. The emerging view 
is that the truncated spliced isoforms may act as a 
inhibitor or regulator for the activity full-length isoforms. 
During our investigations on the functions of GFRα2 
isoforms, we made several observations that led to 
unexpected insights into the inhibitory activity of 
GFRα2b on its isoforms counterparts.  
We have previously shown that GFRα2 isoforms are 
differently expressed in murine brain and peripheral 
tissues[23]. These suggested that all three GFRα2 
isoforms may have significant and distinct physiological 
role in vivo. In this study, we have shown that GFRα2 
isoforms have different activation mechanism and 
distinct functional consequences. More importantly, we 
have shown that GFRα2b antagonizes GFRα2a and 
GFRα2b.  
Dominant negative activity of receptor splice 
variants have been recently shown in other systems, such 
as Glucocorticoid receptor [24], Gonadotropin releasing 
hormone receptor [25] and PPAR receptor [26]. However, 
unlike these dominant negative isoforms, we have now 
shown that MAPK activations and fosB up-regulations in 
GFRα2b isoform and that this isoform was also able to 
attenuate differentiation induced by non- GFRα2 stimuli 
like retinoic acid.  
These indicate that GFRα2b is not merely a 
dominant negative isoform, but more likely to activate 
events that have extensive inhibitory activities. GFRα2 
might be utilizing a yet to be identified mechanism in its 
antagonism and neuritogenesis inhibition. The 
mechanism and signaling pathway(s) involved in 
GFRα2b inhibitory activity is currently being 
investigated. In addition, the potential of GFRα2b in 
inhibiting the differentiation induced by other growth 




GFRα2 isoforms have significant functions, and 
activation mechanisms. We have shown that GFRα2b is 
an inhibitory isoform, which antagonizes GFRα2a and 
GFRα2c. Furthermore, ligand activated GFRα2b was 
able to attenuate retinoic acid induced neuritogenesis. 
Together, these data suggest a new paradigm for the regulation 
of growth factor signaling and neurite outgrowth via an 
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